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Abstract
Background: The anesthetic drug ketamine (KT) has been reported to be an abused drug and
fatal cases have been observed in polydrug users. In the present study, considering the possibility
of KT-enhanced toxic effects of other drugs, and KT-induced promotion of an overdose without
making the subject aware of the danger due to the attenuation of several painful subjective
symptoms, the intraperitoneal (i.p.) KT-induced alterations in behaviors and toxic interactions with
popular co-abused drugs, the psychostimulants cocaine (COC) and methamphetamine (MA), were
examined in ICR mice.
Results: A single dose of KT caused hyperlocomotion in a low (30 mg/kg, i.p.) dose group, and
hypolocomotion followed by hyperlocomotion in a high (100 mg/kg, i.p.) dose group. However, no
behavioral alterations derived from enhanced stress-related depression or anxiety were observed
in the forced swimming or the elevated plus-maze test. A single non-fatal dose of COC (30 mg/kg,
i.p.) or MA (4 mg/kg, i.p.) caused hyperlocomotion, stress-related depression in swimming
behaviors in the forced swimming test, and anxiety-related behavioral changes (preference for
closed arms) in the elevated plus-maze test. For the COC (30 mg/kg) or MA (4 mg/kg) groups of
mice simultaneously co-treated with KT, the psychostimulant-induced hyperlocomotion was
suppressed by the high dose KT, and the psychostimulant-induced behavioral alterations in the
above tests were reversed by both low and high doses of KT. For the toxic dose COC (70 mg/kg,
i.p.)- or MA (15 mg/kg, i.p.)-only group, mortality and severe seizures were observed in some
animals. In the toxic dose psychostimulant-KT groups, KT attenuated the severity of seizures dose-
dependently. Nevertheless, the mortality rate was significantly increased by co-treatment with the
high dose KT.
Conclusion: Our results demonstrated that, in spite of the absence of stress-related depressive
and anxiety-related behavioral alterations following a single dose of KT treatment, and in spite of
the KT-induced anticonvulsant effects and attenuation of stress- and anxiety-related behaviors
caused by COC or MA, the lethal effects of these psychostimulants were increased by KT.
Background
The N-methyl-D-aspartate (NMDA) antagonist ketamine
(KT) is an anesthetic drug used in veterinary practice [1-4].
However, recreational usage as a club drug has also been
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reported, and there are cases of fatal intoxication (e.g. car-
diovascular and respiratory toxicity, etc.) particularly in
polydrug users [5,6]. Recreationally used KT has been
reported to cause euphoric hallucinations such as a feeling
of dissociation of the mind from the body, and due to
these psychotropic effects, the possibility of the disappear-
ance of subjective symptoms accompanying toxicity has
been suggested [7,8]. Furthermore, as this drug causes a
loss of the ability to judge and induces amnesia, the pos-
sibility of its inappropriate usage (e.g. there has been an
increased risk of use of KT as a date rape drug in criminally
victimized individuals, etc.) has been reported [9,10].
Although animal models of complicated psychiatric
symptoms have not been established, some favorable psy-
chological effects (e.g. attenuations of behaviors related to
pain such as anxiety-related behaviors and behavioral
despair) have been reported [11,12]. On the other hand,
an enhancement of the behavioral effects of other abused
drugs (e.g. psychostimulants, etc.), which supports the
increased risk of severe intoxication in human polydrug
abusers, has been observed [13,14]. Therefore, in addition
to a serious enhancement of the toxic effects of other
drugs, it is possible that KT promotes cases of overdose by
attenuating some painful subjective symptoms. In the
present study, considering the importance of warning the
danger associated with KT, the intraperitoneal (i.p.) KT-
induced alterations in behaviors and toxic interactions
with other popular drugs of abuse, the psychostimulants
cocaine (COC) and methamphetamine (MA) [15,16],
were examined in mice.
Results
Alterations in locomotor activity (Fig. 1)
For the KT-only groups (Fig. 1a), at 15 min time point,
aggressive hyperlocomotion was observed and activity
counts were increased as compared to the control group in
the low KT (30 mg/kg)-only group, whereas hypolocomo-
tion accompanied by a loss of the righting reflex was
observed and activity counts were attenuated as compared
to the control group in the high KT (100 mg/kg)-only
group. At 60 min time point, recovery from hyperlocomo-
tion was observed in the low KT-only group, whereas
activity counts in the high KT-only group were signifi-
cantly increased as compared to the control group until
120 min time point.
In the non-fatal dose COC (30 mg/kg)-only and MA (4
mg/kg)-only groups (Fig. 1b, 1c), only at 15 min time
point, hyperlocomotion was observed and activity counts
were increased as compared to the control group.
For the COC and MA groups of mice co-treated with KT
(Fig. 1b, 1c), activity counts at 15 min time point were
attenuated to levels significantly smaller than both the
control and the psychostimulant-only groups, by co-treat-
ment with the high dose (100 mg/kg) KT. Furthermore, in
the psychostimulant plus high KT groups, activity counts
were increased at 60 min time point as compared to both
the control and the psychostimulant-only groups. On the
other hand, in the psychostimulant plus low KT (30 mg/
kg) groups (Fig. 1b, 1c), at 15 min time point, activity
counts were increased to levels as large as the psychostim-
ulant-only groups, and no reversing effects against the
psychostimulant-induced hyperlocomotion were caused
by KT.
The ANOVA analyses revealed significant main effects of
KT treatment, psychostimulant treatment, and test time
[see Additional file 1]. Furthermore, significant interac-
tions between treatments and test times were also
observed, which indicated some time-dependent and KT
dose-dependent changes shown in Fig. 1.
Locomotor activity measured at 15, 60 and 120 min time  points Figure 1
Locomotor activity measured at 15, 60 and 120 min time 
points. The data represent means ± SD (n = 8 for each 
group). A, a: significant increase (A) or attenuation (a) as 
compared to the control group. B, b: significant increase (B) 
or attenuation (b) as compared to the COC- or MA-only 
group.
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Alterations in stress-related depressive behaviors in the 
forced swimming test (Fig. 2)
For the KT-only groups (Fig. 2a), at any time points, no
significant alterations derived from stress-related depres-
sion in swimming behaviors (attenuated time until
immobility and attenuated activity counts) were observed
in each parameter value, and the time until immobility
was increased significantly as compared to the control
group.
In the non-fatal dose COC (30 mg/kg)-only and MA (4
mg/kg)-only groups (Fig. 2b, 2c), stress-related depression
in swimming behaviors was observed, and both time until
immobility and activity counts were significantly attenu-
ated.
For the COC and MA groups of mice co-treated with KT
(Fig. 2b, 2c), recoveries from the alterations in each
parameter value observed in the psychostimulant-only
groups were provided by KT, and there were no significant
differences as compared to the control group.
The ANOVA analyses revealed significant main effects of
KT and psychostimulant treatments [see Additional file
1]. Although significant interactions between KT and psy-
chostimulant treatments were not observed, recoveries
shown in Fig. 2 were provided by KT in the COC and MA
groups.
Alterations in anxiety-related behaviors in the elevated 
plus-maze test (Fig. 3)
For the KT-only groups (Fig. 3a), at any time points, no
significant behavioral alterations derived from anxiety-
related preference for closed arms (attenuated number of
entries into and time spent in open arms, and increased
latency to first open arm entry) were observed in each
parameter value. On the other hand, the number of
entries into open arms and the time spent in open arms
tended to be increased, and the latency to first open arm
entry tended to be attenuated (Fig. 3a-1, 3a-3, 3a-4).
In the non-fatal dose COC (30 mg/kg)-only and MA (4
mg/kg)-only groups (Fig. 3b, 3c), anxiety-related behav-
iors were observed: the number of entries into and time
spent in open arms were attenuated, and the latency to
first open arm entry was increased.
For the COC and MA groups of mice co-treated with KT
(Fig. 3b, 3c), recoveries from the alterations in each
parameter value observed in the psychostimulant-only
groups were provided by KT, and there were no significant
differences, except for increased latency to first open arm
entry, as compared to the control group.
For the locomotor activity on the plus-maze, no quantita-
tive alterations were observed, and there were no signifi-
cant differences in total number of entries into arms
between the groups (Fig. 3a-2, 3b-2, 3c-2).
The ANOVA analyses revealed significant main effects of
KT and psychostimulant treatments, and significant inter-
actions between KT and psychostimulant treatments, for
the number of entries into and time spent in open arms,
and the latency to first open arm entry [see Additional file
1]. However, for the total number of entries into arms, no
significant effects or interactions were observed.
Alterations in toxic effects of high dose COC and MA (Fig. 
4)
For the toxic dose COC (70 mg/kg) and MA (15 mg/kg)
groups, mortality and severe seizures were observed in
some animals even in the psychostimulant-only groups
(Fig. 4), whereas neither mortality nor seizures were
observed in the KT-only groups.
In the groups of mice co-treated with KT, the mortality
rate tended to be increased and was significantly increased
by co-treatment with the high dose KT (Fig. 4a), although
the seizure scores were attenuated significantly by both
low and high doses of KT, in a dose-dependent manner
(Fig. 4b).
Using a 3 (low dose KT, high dose KT versus vehicle) × 2
(toxic dose of psychostimulant COC versus MA) factorial
design, the ANOVA analyses revealed significant main
effects of KT treatment on seizure scores [see Additional
file 1].
Discussion
The anesthetic effects of KT have been reported to be
closely correlated with its antagonistic effects on NMDA
receptors [17,18], but persistent modifications of other
neurons including dopamine (DA), norepinephrine (NE),
and serotonin (5-HT) neurons have also been reported to
accompany the behavioral effects of KT [13,14,19]. These
KT-induced modifications of the neurons in the group of
mice treated with a single KT are different depending on
the dosage [19]: hyperlocomotion observed in both low
and high dose KT groups (Fig. 1a) has been reported to be
correlated with a DA agonist action induced by KT, but
with high KT doses which caused hypolocomotion during
the early period (Fig. 1a), the activation of NE and 5-HT
neurons has also been suggested. In the group of mice
treated with a single COC or MA, the psychostimulant
which exerted KT-like DA agonistic actions [13,14], hyper-
locomotion was also observed (Fig. 1b, 1c). Furthermore,
in the COC- and MA-only groups, unlike in the KT-only
groups, both stress-related depressive behaviors in the
forced swimming test (attenuated time until immobilityBMC Neuroscience 2006, 7:25 http://www.biomedcentral.com/1471-2202/7/25
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Alterations in stress-related depressive behaviors in the forced swimming test Figure 2
Alterations in stress-related depressive behaviors in the forced swimming test. The values for each parameter at 60 and 120 
min time points are shown. The data represent means ± SD (n = 8 for each group). The symbols for differences are the same 
as the other figures.
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Alterations in anxiety-related behaviors in the elevated plus-maze test Figure 3
Alterations in anxiety-related behaviors in the elevated plus-maze test. The values for each parameter at 60 and 120 min time 
points are shown. The data represent means ± SD (n = 8 for each group). The symbols for differences are the same as the 
other figures.
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and attenuated activity counts in the swimming behav-
iors) and anxiety-related behaviors in the elevated plus-
maze test (preference for closed arms, that is, attenuated
number of entries into and time spent in open arms, and
increased latency to first open arm entry) were observed
(Fig. 2b, 2c, 3b, 3c). In the KT-only groups, there were no
such stress-related depressive and anxiety-related behavio-
ral alterations (Fig. 2a, 3a). On the contrary, the parameter
values in the forced swimming test tended to be increased
by KT at levels above those in the control group, which
indicated an attenuation of the stress-related depressive
behavioral alterations below the control level (Fig. 2a).
Furthermore, the KT-induced alterations in parameter val-
ues in the elevated plus-maze test (tendency of increased
number of entries into and time spent in open arms, and
attenuated latency to first open arm entry as compared to
the control group) indicated a preference for open arms,
that is, an attenuation of anxiety-related behavioral alter-
ations below the control level (Fig. 3a). The mechanisms
responsible for these behavioral alterations have not been
elucidated. For the psychostimulant-only groups, the con-
tribution of the neurons which have been reported to be
correlated with stress-related depressive and anxiety-
related behaviors (e.g. DA and benzodiazepine neurons)
[20-23] can be predicted. For the KT-only groups, it is pos-
sible that the behavioral alterations caused by KT were
correlated with the antagonistic effects of KT on NMDA
receptors, considering the fact that NMDA antagonist
actions have been demonstrated at both low and high
doses of KT [24,25]. The contributions of other modified
neurons such as DA, NE, and 5-HT neurons [19] can also
be suspected.
In the non-fatal dose psychostimulant groups of mice co-
treated with KT, the stress-related depressive and anxiety-
related behavioral alterations caused by the psychostimu-
lants were antagonized consistently by both high and low
doses of KT (Fig. 2b, 2c, 3b, 3c). The alterations in loco-
motor activity were also antagonized by the high dose KT
(Fig. 1b, 1c). In our preliminary experiments, the stress-
and anxiety-related behavioral alterations were antago-
nized less effectively by MK-801, a more selective and a
high affinity antagonist for NMDA receptors, which
exerted stronger antagonistic effects on the locomotor
activity than KT [26-28]. Considering these preliminary
results, contributions of other neurons such as DA, NE,
and 5-HT neurons, for which some modifications have
been reported in both psychostimulant and KT treatments
[19,21,23,29,30], could be suspected for the antagonistic
effects of KT. However, further experimental studies are
required for elucidating the mechanisms related to these
neurons for the different behavioral alterations in each
test. In humans, although some unfavorable subjective
effects such as dysphoria have been observed depending
on the dose [31], a characteristic euphoric mind-altering
effect, which may persist subsequent to the appearance of
the "peaceful out-of-body" feeling (a feeling of dissocia-
tion of the mind from the body), has been reported for the
recreational use of KT [5,32]. This sense of euphoric tran-
scendence in humans, which has not been reported for
other amnestic drugs such as thiopental and has been sus-
pected to be the predominant reason for the dependence
on and abuse of KT as a club drug [32], cannot be identi-
fied with the attenuation of stress- and anxiety-related
behavioral alterations in mice shown in the present exper-
iments. However, the attenuation of painful subjective
effects including stress and anxiety has been reported to
increase a preference for drugs in humans [33], and may
promote a dangerous polydrug abuse such as a psychos-
timulant plus KT abuse [5,6]. For the KT-only treatment,
although no significant behavioral abnormalities or fatal
toxicities were observed at or after 120 min time point in
our animal model, it is possible that the absence of stress-
and anxiety-related behavioral alterations promotes fur-
ther use of this drug in humans. Furthermore, for the use
of KT, a significantly greater incidence of abnormalities of
mental status has been reported than for the use of the
other amnestic drugs [34,35]. In rats, a delayed occurrence
of some abnormal behaviors similar to those observed in
Alterations in mortality rate (%) and seizure scores (means ±  SD) in the toxic COC and MA groups (n = 10 for each  group) Figure 4
Alterations in mortality rate (%) and seizure scores (means ± 
SD) in the toxic COC and MA groups (n = 10 for each 
group). The symbols for differences are the same as the 
other figures. In the KT-only groups, neither mortality nor 
seizures were observed (not presented in the figure).
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the model of schizophrenia has been reported for the KT
treatment groups in several behavioral tests [36].
In the groups of mice treated with KT plus a toxic dose
COC or MA, the drug frequently co-abused with KT in
overdose cases [15,16], KT significantly enhanced the
fatality caused by COC or MA in spite of its anticonvulsant
effects. The anticonvulsant effects of KT against COC- or
MA-induced seizures seem to be correlated with NMDA
receptors, based on its antagonistic effects against NMDA-
induced convulsions and the reported contribution of
NMDA receptors to psychostimulant-induced seizures
[37-39]. Furthermore, considering the fact that the anti-
convulsant effects of KT were as strong as MK-801 in our
preliminary experiments, it is possible that receptors other
than NMDA receptors contributed to these effects. For
example, a contribution of GABAA receptors is also pre-
dictable based on the antagonistic effects of KT against the
GABAA antagonist bicuculline-induced seizures and the
reported contribution of GABAA receptors to psychostim-
ulant-induced seizures [40-42]. With respect to the
increase in mortality rate despite the anticonvulsant
effects of KT, the underlying mechanisms have not been
elucidated. However, it is possible that KT directly
enhanced the psychostimulant-induced cardiovascular
and respiratory toxicity. Considering that the behavioral
effects mediated by DA and NE neurons were enhanced by
combining COC with KT [13,14], the toxic peripheral
effects (e.g. cardiovascular effects, etc.) mediated by these
neurons may also be enhanced by the psychostimulant-
KT combination. Therefore, it is possible that KT, like eth-
anol, a drug which increases the lethal effects of COC and
for which behavioral effects similar to KT have been
reported [43-45], enhances the toxic effects of psychos-
timulants without causing severe convulsions or painful
subjective symptoms such as anxiety.
Conclusion
Our results support the contention that the recreational
use of KT is dangerous because, in addition to its toxic
effects with or without combined drugs of abuse, the
accompanying attenuation of some painful subjective
symptoms such as anxiety and stress-related depression
may accelerate the use of the drugs and may promote an
overdose without making the subject aware of the danger.
In our experiments, in addition to the absence of any
stress-related depressive and anxiety-related behavioral
alterations following a single dose KT in the forced swim-
ming and elevated plus maze tests, a KT-induced attenua-
tion of stress- and anxiety-related behaviors caused by
COC or MA was demonstrated. The scores of the seizures
caused by toxic doses of COC or MA were also attenuated
by KT. Nevertheless, the lethal effects caused by toxic
doses of these psychostimulants were increased by KT.
Methods
Animals and drug treatments
Male ICR mice (60–90 days old) (Shizuoka Laboratory
Animal Center, Hamamatsu, Japan) were housed in a
forced-air facility which was maintained at 23°C and 50%
relative humidity, with a 12 h/12 h light/dark cycle
[46,47]. The mice were kept separately in single transpar-
ent cages measuring 23.5 × 16.5 × 12 cm, and were
allowed water and rodent chow ad libitum [46,47]. The
experiments described in this report were conducted in
accordance with the "Guidelines for Animal Experiments"
of our institution (1988), which are based on the
National Institutes of Health Guide for Care and Use of
Laboratory Animals, and any pain experienced by the
mice was minimized.
The dose of ketamine hydrochloride (KT) (Sankyo, Co.,
Ltd., Tokyo, Japan) was selected based on preliminary
experiments and previous studies examining its behavio-
ral effects [11-13,19]. Considering the dose-dependent
effects on various neurons [13,14,19], the experiments
were performed for both low (30 mg/kg) and high (100
mg/kg) doses (low and high KT groups).
For experiments examining the interactions between KT
and psychostimulants, the doses of cocaine hydrochloride
(COC) (Takeda Chemical Industries, Ltd., Osaka, Japan)
and methamphetamine hydrochloride (MA) (Dainippon
Pharmaceutical, Co., Ltd., Osaka, Japan) simultaneously
administered with KT [13,14] were selected based on pre-
liminary experiments and previous studies on their behav-
ioral effects [47-52]. After preliminary experiments, the
COC and MA doses causing effects with similar peak
severity in the behavior and toxicity tests were selected.
For the evaluation of the behavioral effects, a single dose
of 4 mg/kg MA or 30 mg/kg COC was administered with
KT. For the evaluation of the toxic effects, a single dose of
15 mg/kg MA or 70 mg/kg COC was administered with
KT.
For each treatment, i.p. injections were performed. KT,
COC, and MA were administered dissolved in saline to a
volume of 5 ml/kg. In the KT-only groups, the same vol-
umes of saline vehicle were injected instead of COC or
MA. In the COC-only and MA-only groups, the same vol-
umes of saline vehicle were injected instead of KT. In the
control group without any drug treatment (control
group), the same volumes of saline vehicle were injected
instead of both psychostimulants and KT. The drug
administration and each experimental session were per-
formed between 17 and 21 hrs light cycle.
Evaluation of alterations in locomotor activity
Based on previous studies [13,19] and preliminary exper-
iments, alterations (5 min test periods) in locomotorBMC Neuroscience 2006, 7:25 http://www.biomedcentral.com/1471-2202/7/25
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activity caused by the low dose (30 mg/kg) and high dose
(100 mg/kg) KT were observed, and activity counts were
evaluated at 15, 60, and 120 min after the drug treatment
using the activity-measuring and recording system Super-
mex-CompACT AMS instrument (Muromachi Kikai Co.
Ltd., Tokyo, Japan) [47,52].
Evaluation of alterations in behavioral despair (stress-
related depressive behaviors) in the forced swimming test
Based on previous studies [47,52-55], alterations in
behavioral despair in the forced swimming test, which
had been proved to indicate stress-related behavioral
alterations, were examined using a glass cylinder appara-
tus 33 cm in height and 18 cm in diameter containing 14
cm of water at 21–23°C. The time until immobility (the
time after when only modest swimming behaviors neces-
sary to avoid drowning were observed) and the activity
counts for 10 min yielded by swimming behaviors were
evaluated at 60 and 120 min after drug treatment. During
the earlier time point (within 60 min after drug treat-
ment), behavioral effects of the drugs (e.g. a loss of the
righting reflex, etc.) interfered with the swimming behav-
iors, and exposed the mice to the danger of drowning. The
activity was counted using the Supermex-CompACT AMS
instrument by placing the sensor of the instrument over
the cylinder at a distance of 20 cm from the water.
Evaluation of alterations in anxiety-related behaviors in 
the elevated plus-maze test
Based on previous studies [48,52,56], alterations in anxi-
ety-related behaviors were examined by the elevated plus-
maze test using an apparatus that consisted of two oppo-
site open arms 50 × 10 cm (length and width) and two
closed arms 50 × 10 × 30 cm (length, width, and height).
As parameters for the test (5 min test periods), the number
of entries into open arms, the total number of entries into
arms, the time spent in open arms (sec), and the latency
to first open arm entry (sec) were evaluated at 60 and 120
min after drug treatment. During the earlier time point
(within 60 min after drug treatment), due to the notable
alterations in locomotor activity, correct values for anxi-
ety-related behavioral parameters on the plus-maze could
not be obtained. The parameters were evaluated after plac-
ing each mouse diagonally in the center of the maze, fac-
ing both the open and closed arms.
Evaluation of effects on the toxicity of psychostimulants
Using a toxic dose of COC (70 mg/kg) or MA (15 mg/kg),
the effects of KT on mortality and seizures were examined.
The mortality rate (%) and the seizure score (score 0:
absence of seizures; score 1: short-lasting mild seizures;
score 2: short-lasting seizures with a loss of the righting
reflex; score 3: convulsive seizures accompanied by severe
clonus or rearing; and score 4: severe convulsive seizures
continuous and violent enough to cause fatal respiratory
disorders), the score for the most severe episode of sei-
zures in each mouse, were evaluated based on previous
studies [52,57].
Statistical analysis
The data obtained for each treatment at each time point
were subjected to three-way or two-way analysis of vari-
ance (ANOVA) for the factors KT treatment × psychostim-
ulant treatment × test time, or the factors KT treatment ×
psychostimulant treatment, using a 3 (low dose KT, high
dose KT versus vehicle) × 3 (psychostimulant COC, MA
versus vehicle) × 3 (15 min, 60 min versus 120 min) fac-
torial design for the evaluation of locomotor activity, a 3
(low dose KT, high dose KT versus vehicle) × 3 (psychos-
timulant COC, MA versus vehicle) × 2 (60 min versus 120
min) factorial design for the parameters in the forced
swimming and elevated plus-maze tests, and a 3 (low
dose KT, high dose KT versus vehicle) × 2 (psychostimu-
lant COC versus MA) factorial design for the seizure score
[22]. For the parameter values from the forced swimming
and elevated plus-maze tests, the results of ANOVA analy-
ses are summarized in the table [see Additional file 1]. For
pairwise comparisons, post-hoc Bonferroni tests were per-
formed [58]. For comparisons of the mortality rate,
Fisher's exact test was used [52,55]. All of the comparisons
were performed using statistical software packages ('Excel
Statistics' from Social Survey Research Information Co.
Ltd. Inc., Tokyo, Japan). Unless otherwise noted, P values
less than 0.05 were considered to be statistically signifi-
cant.
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